Bladder cancer is a common malignancy, with an estimate of nearly 75,000 new diagnoses in the United States in 2014.1 Although CT and MRI are the most widely used imaging modalities for bladder cancer evaluation, both of these modalities share common limitations. Mural inflammation from a series of interventions commonly applied in these patients, including transurethral bladder tumor resections, biopsies, and intravesical Bacillus Calmette-Guerin therapy, can contribute to misinterpretations on imaging in terms of the presence and stage of residual tumor as well as the differentiation of recurrent tumor from chronic reactive changes.2–4 In addition, both CT and MRI, including MRI with diffusion-weighted imaging (DWI), are limited in determining the presence of metastatic lymph nodes.5,6 Although PET has also received attention for bladder cancer evaluation,7,8 standard 18F-FDG PET is limited by free excretion of FDG into the urine and subsequent high accumulation within the bladder lumen.9 This accumulation obscures, if not entirely masks, focal bladder lesions. In addition, alignment of the bladder between the PET and CT acquisitions in PET/CT is recognized to be suboptimal.10 Therefore, FDG PET has historically had a very limited role in bladder cancer evaluation in clinical practice.9 Recent protocol advances suggest that FDG PET may in fact have greater potential for bladder cancer assessment than previously considered. A number of investigations have explored a forced diuresis protocol entailing, most commonly, oral hydration, IV diuretic administration, and subsequent voiding, performed between radiotracer administration and PET imaging.9,11,12 This approach is intended to achieve clearance of excreted FDG from the bladder lumen while allowing for persistent uptake within the bladder wall itself. Recent studies of PET/CT using this approach have shown that bladder tumors indeed are consistently FDG avid and can be well visualized by PET.12,13 In addition, small metastatic pelvic lymph nodes have been reported to exhibit increased activity using 18F-FDG PET/CT, further supporting the potential value of PET for bladder cancer assessment.14,15 Although such methodological advances are encouraging, the ability to fully characterize bladder cancer is inherently limited using PET/CT. First, using the forced diuresis protocol, the bladder is actively reexpanding at the time of imaging, thus undergoing changes in shape and volume over time. Given that PET and CT are performed in sequential, rather than truly simultaneous, fashion using PET/CT, these dynamic changes of the bladder likely contribute to the recognized misregistration of the bladder between PET and CT acquisitions, even when obtained consecutively during a single examination.10 Patient motion may interfere with accurate coregistration as well, not just of the bladder itself, but also of other important pelvic structures such as small lymph nodes. Finally, the muscularis propria, a critical anatomic landmark in the staging of bladder cancer, is not well visualized as a distinct layer within the bladder wall on CT, further hindering comprehensive tumor evaluation by PET/CT.16 The advent of integrated PET/MRI scanners provides a novel imaging approach that may further improve upon recent advances in PET/CT in numerous respects.17 In PET/MRI, the acquisitions are spatially and temporal simultaneous, such that the degree of bladder filling and consequent bladder volume and shape are essentially identical between the PET and MRI image sets. This truly simultaneous acquisition is likely to also help compensate for the impact of patient motion on registration of the bladder and other pelvic structures. In addition, the higher contrast resolution of MRI, as compared with CT, allows improved delineation of the muscularis propria of the bladder wall and thereby improved local staging.16 Moreover, MRI offers a multiparametric approach that provides, along with anatomic assessment, quantitative metrics, including measures derived from DWI and dynamic contrast-enhanced (DCE) MRI. Such metrics have shown significant associations with bladder cancer aggressiveness in past studies.18,19 Furthermore, simultaneous PET allows for determination of SUV as an additional metric that can be incorporated into a multiparametric panel for bladder cancer assessment. Although integrated PET/MRI systems have generated a large amoun of interest, these systems entail a large financial investment and are only being used clinically at a small number of centers. Centers may instead elect to separately perform conventional PET and MRI scans, with subsequent retrospective fusion. Therefore, the benefit of simultaneous imaging, as is only achievable with an integrated system, is important to investigate in order to ascertain such a system’s true value. Bladder cancer provides an appropriate setting for such an investigation given the dynamic changes in bladder size and shape during short time intervals over the course of a single scan. In this study, our aim was to compare the accuracy of coregistration of the bladder wall, bladder lesions, and pelvic lymph nodes between sequential and simultaneous acquisitions obtained during 18F-FDG PET/MRI performed using a forced diuresis protocol in bladder cancer patients.